BioStem Technologies, Inc. has filed its audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2025, positioning the company closer to a Nasdaq uplisting. The financial documents are available for public review on the OTC Markets website at https://www.otcmarkets.com/stock/BSEM/disclosure. This publication represents a critical milestone in BioStem's corporate development, following recent appointments of a new CFO, auditor, and audit committee chair.
Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated that the achievement underscores the company's efforts to establish robust financial reporting processes. He emphasized that listing on Nasdaq remains a top priority, as it would increase visibility, improve stock liquidity, provide a more precise market valuation, and enhance the company's ability to attract top talent. BioStem, which trades on the OTC market under the symbol BSEM, focuses on developing, manufacturing, and commercializing perinatal tissue allograft products for regenerative medicine.
The company utilizes proprietary processing technologies including BioRetain®, CryoTek®, and SteriTek® to preserve tissue properties for clinical use. Its product portfolio includes the Neox®, Clarix®, VENDAJE®, and American Amnion™ brands, which are used by clinicians across various specialties. BioStem's quality management system is accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and current Good Manufacturing Processes. For more information about the company, visit https://biostemtechnologies.com.
This development matters because uplisting to a major exchange like Nasdaq typically signals greater financial transparency and corporate maturity, which can increase investor confidence and potentially broaden the shareholder base. For the regenerative medicine industry, BioStem's progress demonstrates how smaller biomedical companies can advance through regulatory and financial milestones to access larger capital markets. The move could impact stock liquidity and valuation accuracy for current investors, while potentially attracting institutional investment that might accelerate the company's research and commercialization efforts in tissue-based therapies.
